Description
Co Dopa CR 125 mg is a controlled-release formulation used in the treatment of Parkinson’s disease and related movement disorders. Each tablet contains Levodopa 100 mg and Carbidopa 25 mg, which work together to increase dopamine levels in the brain and improve motor symptoms such as tremor, rigidity, and bradykinesia.
The controlled-release (CR) formulation allows for slower, more consistent absorption, helping to maintain more stable dopamine levels and reduce "off" periods or fluctuations in symptom control.
 250 ML.jpeg)
 15ML.webp)
 200ML.webp)
 100ML.png)
 20ML.jpeg)
 125ML.webp)
.webp)
 125ML.jpg)
 200ML.webp)
 50ML.webp)
 200 ML.jpeg)
 30 TAB.webp)
 40 ML.png)
 150GM.webp)
 200ML.jpg)
.webp)
60 ML 60 ML.webp)
Change Language